HTG EdgeSeq Immuno-Oncology Assay

HTG Molecular Diagnostics has launched the EdgeSeq Immuno-Oncology assay for digitally measuring the mRNA expression of 549 genes implicated in the host immune response to tumors. Automated on the HTG EdgeSeq system, the research-use-only assay couples HTG's proprietary nuclease protection chemistry with next-generation sequencing. With the new assay, researchers can measure the expression level of drug targets, determine tumor infiltrate composition, and assess total immune cell composition using a single section of FFPE tissue, the company said.